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Abstract
Background: Susceptibility/resistance to Plasmodium falciparum malaria has been correlated with
polymorphisms in more than 30 human genes with most association analyses having been carried
out on patients from Africa and south-east Asia. The aim of this study was to examine the possible
contribution of genetic variants in the TNF and FCGR2A genes in determining severity/resistance to
P. falciparum malaria in Indian subjects.
Methods: Allelic frequency distribution in populations across India was first determined by typing
genetic variants of the TNF enhancer and the FCGR2A G/A SNP in 1871 individuals from 55
populations. Genotyping was carried out by DNA sequencing, single base extension (SNaPshot),
and DNA mass array (Sequenom). Plasma TNF was determined by ELISA. Comparison of datasets
was carried out by Kruskal-Wallis and Mann-Whitney tests. Haplotypes and LD plots were
generated by PHASE and Haploview, respectively. Odds ratio (OR) for risk assessment was
calculated using EpiInfo™ version 3.4.
Results: A novel single nucleotide polymorphism (SNP) at position -76 was identified in the TNF
enhancer along with other reported variants. Five TNF enhancer SNPs and the FCGR2A R131H (G/
A) SNP were analyzed for association with severity of P. falciparum malaria in a malaria-endemic
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from both regions. TNF -1031C and -863A alleles as well as homozygotes for the TNF enhancer
haplotype CACGG (-1031T>C, -863C>A, -857C>T, -308G>A, -238G>A) correlated with
enhanced plasma TNF levels in both patients and controls. Significantly higher TNF levels were
observed in patients with severe malaria. Minor alleles of -1031 and -863 SNPs were associated
with increased susceptibility to severe malaria. The high-affinity IgG2 binding FcγRIIa AA (131H)
genotype was significantly associated with protection from disease manifestation, with stronger
association observed in the malaria non-endemic region. These results represent the first genetic
analysis of the two immune regulatory molecules in the context of P. falciparum severity/resistance
in the Indian population.
Conclusion: Association of specific TNF and FCGR2A SNPs with cytokine levels and disease
severity/resistance was indicated in patients from areas with differential disease endemicity. The
data emphasizes the need for addressing the contribution of human genetic factors in malaria in the
context of disease epidemiology and population genetic substructure within India.
Background
The association of severity of malaria with several human
genetic factors is well documented [1] and the disease has
been the selective pressure behind several erythrocytic
defects such as sickle cell disease, G6PD deficiency and
thalassaemia [2,3]. Malaria susceptibility/resistance has
been correlated with polymorphisms in more than 30
other genes, some of which have exhibited differential
association in distinct populations of the world [1]. Plas-
modium falciparum blood infection levels and fever epi-
sodes have been linked to chr 5q31–33 [4] and chr10 [5].
While most human gene polymorphism-disease associa-
tion studies for malaria susceptibility have been carried
out on populations from Africa and south-east Asia, there
is limited information on malaria-associated gene poly-
morphisms in Indian populations [6-8].
Incidence of P. falciparum malaria in India is high with
~0.9 million cases reported annually in the last few years
[9]. Several regions of the country are 'high risk' for P. fal-
ciparum with the infection accounting for more than 80%
of all malaria cases in certain areas [10,11] (Figure 1d).
The population of India represents largely endogamous
groups comprising distinct religious communities, castes
and isolated tribal populations. The Indian population is
genetically heterogeneous as revealed by recent Indian
Genome Variation Consortium (IGVC) data on 55 sub-
populations of the country [unpublished data]. As differ-
ences in genetic structure (population stratification),
selection and human adaptation are major confounders
in association studies, it is important that case-control
association studies for malaria in India be carried out on
carefully defined, ethnically-matched sets of patients and
controls.
Single nucleotide polymorphisms (SNPs) in the 5' regula-
tory region of TNF and coding region of FCGR2A have
been associated with P. falciparum malaria [12-17].
Tumour Necrosis Factor (TNF) is involved in multiple
inflammatory and immune responses and plays an
important role in the pathogenesis of many infectious dis-
eases including P. falciparum malaria [18]. The transcrip-
tion of TNF is complex and tightly regulated [19,20].
SNPs in the 5' regulatory region of the gene have been
shown to correlate with many infectious and inflamma-
tory diseases [21,22] with conflicting reports regarding
their functional significance. SNPs at positions -1031, -
857, -376 (rs1800750, G>A), -308 and -238 in the proxi-
mal enhancer of the TNF gene exhibit differential associa-
tions to malaria and TNF production in different
populations [12-14,23-25] suggesting that individual TNF
responses may be genetically determined.
The human IgG receptor FcγRIIa (CD32) is an important
link between the cellular and humoral arms of the
immune system. It is a low affinity receptor for immu-
noglobulin subtypes IgG1–4 and also binds C-reactive
protein (CRP) with high affinity. A polymorphism in
exon 4 of FCGR2A (R131H, G/A) alters its function in
vitro; the product of the G allele (131R) has preferential
affinity for IgG1 and IgG3 while the A allele (131H) prod-
uct binds efficiently to IgG2 while retaining its affinity for
IgG1 and IgG3 [26]. The high-affinity IgG2 binding 131H
allele has been correlated with susceptibility to severe P.
falciparum malaria in Africa, particularly in children in
Kenya and Gambia [15,16], but failed to show significant
independent association with severity of malaria in Thai
adults [27]. A recent report [17] has implicated the 131H
allele in protection from severe malaria in Sudan.
Screening of the enhancer region of the TNF gene for
genetic variants in the ethnically diverse Indian popula-
tion and correlation of two SNPs (-1031 and -863) with
circulating plasma TNF levels in healthy individuals and
P. falciparum malaria patients is reported here. Correlation
of TNF levels and 5' regulatory region SNPs with severityPage 2 of 11
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patients and controls drawn from a P. falciparum endemic
and a non-endemic region of the country. The FcγRIIa
R131H polymorphism was also evaluated for correlation
with susceptibility to severe malaria in these regions.
Methods
Study subjects and sample collection
Analysis of allele frequency distribution of the selected
TNF (RefSeq NT_007592.14) and FCGR2A (RefSeq
NM_021642) SNPs was carried out in the existing Indian
Genome Variation Consortium (IGVC) samples. This val-
idation panel consisted of 1,871 samples drawn from 55
ethnically and linguistically diverse endogamous popula-
tions across India [28].
For the case-control study for an endemic (Antagarh,
Chhattisgarh and Sundargarh, Orissa) and a non-endemic
(Lucknow and surrounding areas of Uttar Pradesh) region
(Figure 1a), approval was obtained from ethical commit-
Gradient maps representing genotype frequency distribution of the minor allele of TNF promoter/enhancer and FCGR2A G/A R131H SNPs across IndiaFigur  1
Gradient maps representing genotype frequency distribution of the minor allele of TNF promoter/enhancer and FCGR2A G/A 
R131H SNPs across India. A, rs1799964 (-1031T>C); B, rs1800630 (-863C>A); C, rs1801274 (exon4 G>A). Dots on each map 
depict the 55 IGVC endogamous populations. Ho and FST value of each SNP is indicated. D, map depicting P. falciparum malaria 
prevalence across the country as percentage of all malaria cases. Areas where incidence is >30% are considered 'high risk'. E, 
distribution of TNF enhancer haplotypes for the SNPs -1031T>C, -863C>A, -308G>A, -238G>A, -76T>C across Indian popu-
lations. The linguistic lineages (TB, Tibeto-Burman; IE, Indo-European; DR, Dravidian; AA, Austro-Asiatic) of populations are 
indicated. Endogamous populations that contributed to patient and control samples from the endemic and non-endemic region 
are marked by * and #, respectively in A and E. Blue and green circles in A represent patient recruitment sites in the P. falci-
parum-endemic and -non-endemic region, respectively.Page 3 of 11
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obtained from each volunteer/guardian prior to collec-
tion. Blood samples (2 to 5 ml) were drawn from patients
above five years of age diagnosed with P. falciparum
malaria. Diagnosis was carried out by rapid diagnostic test
kits (Optimal/Paracheck) followed by confirmation by
examination of thick and thin film blood smears. Catego-
rization of severe and non-severe cases was performed
according to WHO guidelines [29]. Non-severe malaria
patients were blood smear-positive, had fever and lacked
symptoms that characterized severe malaria. Severe
malaria cases were categorized as cerebral and non-cere-
bral. Cerebral malaria was characterized by impaired con-
sciousness (coma) with fever. Any one of the following
symptoms together with a positive blood smear indicated
severe (non-cerebral malaria): severe anaemia, acidotic
breathing, pulmonary oedema, hypoglycaemia, increased
serum creatinine levels. A total of 121 patients (68 and 53
patients from the endemic and non-endemic region,
respectively) and 100 healthy control individuals (42 and
58 uninfected individuals from the endemic and non-
endemic region, respectively) were included in the study.
Plasma TNF levels in the context of disease severity were
analyzed for 175 patients (101 and 74 patients from the
endemic and non-endemic region, respectively) and 186
control individuals (98 and 88 individuals from the
endemic and non-endemic region, respectively). Control
samples were taken from ethnically-matched, unrelated
individuals from the endemic region and non-endemic
region. Plasma was separated at the time of collection and
stored in liquid nitrogen. G6PD level and HbA/S status of
each individual was determined.
Genomic DNA extraction and genotyping
Genomic DNA was extracted from peripheral blood leu-
cocytes using salting-out procedure [30]. For validation of
reported SNPs and discovery of novel SNPs, a 511 bp
region of the TNF enhancer (-1 to -511) was sequenced in
a discovery panel comprising 43 samples from different
populations of India [28]. Genotyping of all TNF and
FCGR2A SNPs in the IGVC validation panel was done by
Sequenom mass spectroscopy. For patient and control
samples, genotyping of -1031, -863 and -857 TNF SNPs
was done by direct sequencing of a 292 bp PCR product
covering nt -782 to -1073. Typing of other TNF SNPs (-
308, -238, -76) and FCGR2A G/A (R131H) SNP was done
by SNaPShot method (Applied Biosystems). All DNA
sequencing and genotyping was performed on 3130xl
automated DNA sequencer (Applied Biosystems).
Approximately 10% genotypings carried out by SNaPshot
were quality checked by DNA sequencing.
ELISA for TNF
A sandwich ELISA was performed to measure plasma TNF
levels using capture monoclonal anti-human TNF anti-
body (Pierce) and a paired biotinylated anti-human TNF
antibody (Pierce). The minimum detection limit of the
assay was 2 pg/ml.
Statistical methods
The chi-square test was performed to evaluate whether the
allele frequencies of the populations are in Hardy-Wein-
berg equilibrium. Comparison of TNF levels among gen-
otypes of the -1031 and -863 SNPs was carried out by
non-parametric Kruskal-Wallis test [31]. Pairwise compar-
ison of means for TNF levels was carried out by Mann-
Whitney test. Haplotypes for TNF SNPs were generated by
PHASE. Linkage disequilibrium (LD) plot for TNF SNPs
was generated using Haploview. Odds ratio (OR) for risk
assessment was determined using EpiInfo™ version 3.4
software with the P-value calculated by Fisher Exact or
Mantel-Haenszel test.
Results
TNF regulatory region and FCGR2A SNP frequencies 
vary across Indian populations
Validation of reported TNF 5' regulatory region polymor-
phisms as well as discovery of possible novel SNPs in TNF
promoter/enhancer was carried out by sequencing in rep-
resentative samples of 43 populations of India (discovery
panel) under the Indian Genome Variation Consortium
(IGVC) [28]. A novel SNP, -76 T>A (allotted SNP ID:
rs41297589), was discovered in the Indian population.
Validation of the SNP in the larger panel comprising 1871
samples from 55 populations across India revealed an
overall minor allele frequency (MAF) of 0.031. Forty pop-
ulations, across all linguistic lineages, were polymorphic
at this site (Figure 2). This SNP lies within the nt -131 to -
63 region of the TNF enhancer that has been reported to
be highly conserved in humans and primates [32] and is
positioned at the low affinity transcription factor Ets-1
binding site in macrophages and the high affinity NFATp
binding site in T and B cells [19]. Of the SNPs analyzed
under IGVC, the TNF -76 T>A was among those exhibiting
the lowest FST and heterozygosity (Ho) values (FST = 0.017,
Ho = 0.052) suggesting negative selection. The distribu-
tion of TNF SNPs at positions -1031, -863, -308 and -238
across Indian populations is shown in Figure 1 and Figure
2. The frequency of the A allele of the FCGR2A exon 4 G/
A R131H polymorphism across the 55 populations varied
from 0.38 to 0.83. The distribution of the AA genotype is
shown in Figure 1c. Allele frequency information for these
SNPs across all populations may be accessed through the
IGVC website [33].
This SNP frequency data was used to plan a case-control
study to analyze the association of TNF and FCGR2A SNPs
with P. falciparum malaria in India. Patient samples were
collected from a P. falciparum-endemic area (Chattisgarh
and Orissa) that has perennial and high malaria transmis-Page 4 of 11
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low and seasonal transmission. The main affected popu-
lations of the endemic region are isolated tribal groups of
the Austro-Asiatic and Dravidian linguistic lineage while
the patients in the non-endemic region are primarily from
large populations (caste and religious groups) of the Indo-
European lineage. Mean MAFs from populations of these
regions covered by IGVC were compared (Table 1); allele
frequencies of five populations from the non-endemic
region (n = 197) and three populations from the endemic
region (n = 86) were analyzed. Significant differences
between the endemic and non-endemic region were
Minor allele frequency (MAF) distribution of TNF SNPs across IndiaFigu e 2
Minor allele frequency (MAF) distribution of TNF SNPs across India. A, rs1799964 (-1031); B, rs1800630 (-863); C, rs1800629 
(-308); D, rs361525 (-238); E, rs41297589 (-76).
0.0 0.299
rs1800629
0.0 0.129
rs41297589
Fst= 0.017
Ho=0.052
rs361525
0.0 0.17
0.0 0.64
rs1799964 rs1800630
0.0 0.638
A B
C D E
Table 1: TNF enhancer and FCGR2A SNP frequencies in IGVdb populations from the P. falciparum endemic and non-endemic regions 
included in this study.
Position dbSNP ID Minor allele frequency P value
TNF Non-endemic Endemic
-1031 (T>C) rs1799964 0.314 0.436 0.013
-863 (C>A) rs1800630 0.242 0.405 0.003
-308 (G>A) rs1800629 0.062 0.063 0.97
-238 (G>A) rs361525 0.075 0.080 0.92
-76 (T>A) rs41297589 0.030 0.054 0.338
FCGR2A
Arg/His, G/A rs1801274 0.568 0.66 0.07Page 5 of 11
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of the FCGR2A (R131H) A allele was also higher in the
endemic region although the P value was 0.07. Thus, the
healthy control panel constituted for this study comprised
ethnically-matched individuals from both regions. The
combined control panel comprised equivalent numbers
from both these groups and included populations repre-
sented in the patient pool.
Homozygotes of TNF -1031C and -863A alleles are 
associated with elevated circulating TNF levels
The five TNF regulatory region SNPs described above as
well as the -857 SNP previously correlated with cerebral
malaria [13] were typed in patients and controls. As the -
857, -308, -238 and -76 SNPs had relatively low fre-
quency, only the -1031 and -863 SNPs were analyzed fur-
ther.
Within the patient and control groups, significant differ-
ences in TNF levels were seen between genotypes of both
-1031 and -863 (-1031, P = 0.0178 and 0.0089; -863, P =
0.0481 and 0.023 in controls and patients, respec-
tively)(Table 2). Comparison between homozygotes indi-
cated significant correlation of high TNF levels with the
minor allele of both SNPs (P < 0.01) (Table 2). Although
heterozygotes had higher levels than major allele
homozygotes in both patients and controls, the difference
was statistically non-significant.
The -1031 and -863 SNPs had a similar distribution pat-
tern in Indian populations (Figure 1, Figure 2). Combined
analysis of the patient and control groups indicated that
alleles of -1031 and -863 were in linkage disequilibrium
(LD) (D' = 0.73, r2 = 0.494) while no linkage was observed
with -308 and -238 (Figure 3a). Haplotype analysis of the
control groups revealed that the CACGG haplotype (-
1031C, -863A, -857C, -308G, -238G) in which both -
1031 and -863 were mutated had the highest frequency
(0.115) after the major haplotype TCCGG (0.58). The
CAGGT haplotype (-1031C, -863A, -308G, -238G, -76T),
polymorphic at -1031 and -863, was the predominant
haplotype after the major haplotype TCGGT in the IGVdb
populations as well (Figure1e). Thus, the possible correla-
tion between TNF levels and the CACGG haplotype was
investigated by comparing TNF levels in subjects that were
homozygous for the CACGG haplotype and the major
haplotype TCCGG. Individuals homozygous for CACGG
from both patient and control groups had significantly
higher TNF levels than those homozygous for TCCGG (P
= 0.0001) (Figure 3b) indicating strong association of the
haplotype with elevated TNF levels.
High TNF levels correlate with severe P. falciparum 
malaria
Elevated TNF levels in malaria patients have been corre-
lated with severe disease manifestation in other world
populations [34,35] although significant differences
between plasma TNF levels were not observed between
uncomplicated, severe anemia, and cerebral malaria
patients in a recent report on Malian children [23] sug-
gesting the possibility of population-specific differences.
An earlier study from India [36] reported higher TNF level
in patients with multiple organ dysfunction and those
who died. Our results indicated significantly higher TNF
levels in patients with severe P. falciparum malaria when
compared with controls (P < 0.0001) or with patients
with non-severe malaria (P = 0.0009) (Figure 3c). The dif-
ference in TNF levels between non-severe patients and
controls was not significant (P = 0.25). Significant differ-
ences were not seen between non-cerebral severe and cer-
ebral malaria patients (P = 0.102) suggesting correlation
with severe disease manifestation including cerebral
malaria.
Table 2: Correlation of TNF levels with genotypes of the -1031 and -863 SNPs in controls and patients. Comparison of means was 
carried out by Kruskal-Wallis test.
TNF levels as mean ± S.D. (pg/ml)
Controls (n = 100) Patients (n = 111)
-1031
TT 18.2 ± 22.17 (n = 58) P = 0.0178 27.9 ± 29.14 (n = 58) P = 0.0089
TC 21.3 ± 23.2 (n = 36) 40.9 ± 64.9 (n = 47)
CC 56.56 ± 35.1 (n = 6)a 126.6 ± 80.82 (n = 6)b
-863
CC 19.01 ± 22.9 (n = 61) P = 0.0481 25.6 ± 29.3 (n = 62) P = 0.0231
CA 17.79 ± 17.9 (n = 30) 47.5 ± 66.8 (n = 44)
AA 52.27 ± 35.1 (n = 9)c 124.7 ± 90.2 (n = 5)d
'n' indicates number of individuals in each category.
a,b TNF levels in TT vs. CC in controls and patients: P < 0.01 (Mann-Whitney test)
c,d TNF levels in CC vs. AA in controls and patients: P < 0.02 (Mann-Whitney test)Page 6 of 11
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to severe P. falciparum malaria
The -1031C allele was associated with disease severity
with higher percentage of the mutant genotypes observed
in severe patients compared with controls (55.5% versus
42%, OR = 1.76, 95% CI = 0.97–3.2, P = 0.048) (Table 3).
A similar trend was observed for the -863A allele (51.7%
versus 39%, OR = 1.69, 95% CI = 0.93–3.09, P = 0.065).
Significant difference in distribution of the minor allele
for both -1031 and -863 was also observed between severe
and non-severe patient groups (-1031, 55.6% versus
40.4%, OR = 1.87, 95% CI = 1.03–3.4, P = 0.028; -863,
51.85% versus 36.8%, OR = 1.84, 95% CI = 1.01–3.38, P
= 0.033) indicating association of the minor allele with
disease severity. Interestingly, when severe cases were ana-
lyzed separately as non-cerebral severe (NCM, n = 33) and
cerebral malaria (CM, n = 21), stronger association of the
-1031C allele was indicated with non-cerebral severe
malaria as compared to cerebral malaria (CM versus non-
severe, OR = 1.38, 95% CI = 0.76–2.52, P = 0.25; NCM
versus non-severe, OR = 2.25, 95% CI = 1.23–4.13, P =
0.004) suggesting association of the minor allele with
non-cerebral but not cerebral severe disease manifesta-
tion. Taken together, our data indicated a strong correla-
tion between the TNF -1031 and -863 SNPs and cytokine
levels in individuals, association of high TNF level with
severe malaria as well as correlation of -1031C and -863A
polymorphisms with disease severity.
In light of the differential association reported for the
FCGR2A G/A (R131H) polymorphism with P. falciparum
malaria in different populations, we analyzed its distribu-
tion in patient and control groups. Combined analysis of
endemic and non-endemic region samples indicated that
the high affinity IgG2-binding 131H allele associates with
protection from disease manifestation; the GG homozy-
gote for 131R correlated with susceptibility to severe
malaria (severe vs. control, OR for GG and AA = 3.9, P =
0.026) (Figure 4). Heterozygote for the G allele also corre-
lated with manifestation of disease (severe vs. control, OR
for GA and AA = 2.56, P = 0.013; non-severe vs. control,
OR for GA and AA = 2.73, P = 0.01) (Figure 4). No signif-
Table 3: Genotype distribution of TNF regulatory region SNPs in controls and patients.
Control (n = 100) Non-severe (n = 57) Severe (n = 54)
-1031
TT 58 (58%) 34 (59.6%) 24 (44.4%)
TC 36 (36%) 21 (36.8%) 26 (48.1%)
CC 6 (6%) 2 (3.5%) 4 (7.4%)
-863
CC 61 (61%) 36 (63.1%) 26 (48.1%)
CA 30 (30%) 19 (33.3%) 25 (46.2%)
AA 9 (9%) 2 (3.5%) 3 (5.5%)
Linkage between TNF regulatory region SNPs and correlation of TNF haplotypes with plasma TNF levelsFigur 3
Linkage between TNF regulatory region SNPs and correlation 
of TNF haplotypes with plasma TNF levels. A, r2 LD plot of 
four TNF SNPs (-1031, -863, -308, -238). Value in each cell is 
the percent D' between SNP pairs. B, Correlation of TNF 
promoter haplotype (-1031C, -863A, -857C, -308G, -238G) 
with elevated TNF levels compared to the major haplotype 
TCCGG. Mean plasma TNF levels were compared using 
Mann-Whitney test (z = -3.73, P = 0.0002). C, Plasma TNF 
level in patients and controls. Pairwise comparison of means 
by non-parametric Mann-Whitney test: severe versus con-
trol, z = 4.41, P < 0.0001; non-severe versus control, z = 
0.67, P = 0.25; severe versus non-severe, z = 3.13, P = 
0.0009.
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and GG genotypes in different disease groups (P > 0.05 in
all odds ratio calculations). The 131H/H genotype was
associated with protection with the control group having
a significantly higher proportion of the AA genotype com-
pared to the non-severe (41.3% versus 20.3%, OR = 2.78,
95% CI = 1.41–5.5, P = 0.001) and severe (41.3% versus
20.6%, OR = 2.61, 95% CI = 1.34–5.13, P = 0.002) patient
groups. After stratifying for populations in the endemic
and non-endemic region, a stronger association of the G
allele with severe malaria was observed in the non-
endemic region (severe vs. control, OR for GG and AA =
4.67, 95% CI = 0.75–33.94, P = 0.047 in non-endemic
region and OR for GG and AA = 2.83, 95% CI =
0.17–33.76, P = 0.32 in endemic region; severe vs. con-
trol, OR for GA and AA = 2.59, 95% CI = 0.93–7.4, P =
0.043 in non-endemic region and OR for GA and AA =
2.43, 95% CI = 0.5–12.06, P = 0.178 in endemic region).
Our results indicate that the 131R allele is associated with
susceptibility to disease with the 131H/H genotype being
protective against P. falciparum malaria and suggest differ-
ences in FcγRIIa R131H allelic association profiles in
regions with differential P. falciparum prevalence and
transmission.
Discussion
The role of TNF during P. falciparum malaria infection has
been described as both protective and pathogenic [37,38].
At low levels, TNF is believed to augment parasite killing
by macrophage activation and subsequent release of
cytokines, whereas high TNF level has been associated
with severe manifestations like acute respiratory distress
and cerebral malaria. A recent study on lethal malaria in
mice has implicated high levels of TNF in impairment of
dendritic cell function thus contributing to immunosup-
pression associated with malaria [39]. Individual varia-
tion in TNF production mainly by macrophages and NK
cells is likely to influence severe disease manifestation.
Although the effect of TNF enhancer SNPs on transcrip-
tion levels of the cytokine remains controversial [40,41],
several studies have implicated their role in determining
TNF levels in individuals and consequently influencing
their response to a gamut of autoimmune and infectious
diseases including P. falciparum malaria [42,43]. While
association of the -863A substitution with reduced TNF
levels was described in the Swedish population [44], a
study from Japan [45] reported association of the -1031, -
863 and -857 polymorphisms with increased reporter
gene expression and increased concanavalin A-stimulated
TNF production from peripheral blood mononuclear
cells. Additionally, the ubiquitous transcription factor
OCT-1 has been reported to exhibit allele-specific binding
to the variant allele -863A or -857T [46]. In our study as
well, higher circulating TNF levels in both controls and
patients were associated with the -1031C and -863A poly-
morphisms. The two SNPs were in LD and the CACGG
haplotype (-1031C, -863A, -857C, -308G, -238G) was
strongly associated with higher plasma TNF levels. This
haplotype had the highest estimated frequency in controls
(0.115) after the major haplotype TCCGG (0.58). As the -
1031 and -863 polymorphisms are present in high fre-
quency in India and the CAGGT haplotype (-1031C, -
863A, -308G, -238G, -76T) is also the predominant hap-
lotype after the major haplotype TCGGT in most of the 55
IGVdb populations analyzed by us, the two SNPs may
play a significant role in modulating the immune
response and influencing the outcome of several infec-
tious diseases.
Our results indicated association of the -1031 and -863
TNF SNPs with increased risk of severe malaria. A recent
study on Thailand/Myanmar border populations reported
association of the TNF -1031C, -863C, -857C allele with
Correlation of FCGR2A G/A R131H polymorphism with P. fal-ciparum malaria in combined analysis f samples from the endemic and non-endemic regionFigure 4
Correlation of FCGR2A G/A R131H polymorphism with P. fal-
ciparum malaria in combined analysis of samples from the 
endemic and non-endemic region. Genotype frequency dis-
tribution in controls and patients is depicted. Odds ratios 
(OR) indicate association of the G allele with increased risk 
of malaria.
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with HLA-DRB1 and HLA-B alleles indicating that associ-
ation with susceptibility to cerebral malaria was not
because of LD with the HLA alleles. To our knowledge,
our study is the first report of independent association of
the -863 polymorphism with increased risk of severe dis-
ease.
In contrast to previous reports [15,16,27], our data impli-
cates the low-IgG2 binding 131R allele in susceptibility to
P. falciparum malaria with the high-affinity IgG2 binding
131H/H genotype being associated with protection from
disease. Our results are in agreement with a recent study
on subjects from Sudan that demonstrated that the 131R/
R genotype and the 131R allele were significantly associ-
ated with the odds of severe malarial disease [17]. The
131H/H genotype was associated with a reduced risk of
both non-severe and severe malaria in our study, indicat-
ing a role for the polymorphism in protection from clini-
cal manifestation of disease. The FcγRIIa 131H receptor
binds IgG3 more efficiently than 131R and is the only
high-affinity receptor for IgG2 [47,48]. Cytophilic anti-
bodies are thought to be critical in protective immunity
and several studies have shown an association between
increased levels of IgG1 and IgG3 subclasses and protec-
tion from malarial infection or disease [49-51]. High lev-
els of IgG2 antibodies to MSP-2 and RESA have been
associated with resistance to P. falciparum malaria in
Burkina Faso [52]. IgG2 antibodies may be cytophilic in
individuals carrying the 131H allele as these bind Fcγ
receptor with greater affinity. Nasr et al. [17] showed that
IgG3 antibodies specific to crude malarial antigen were
more associated with reduced risk of clinical malaria in
131H/H individuals than in 131R/R individuals; weak but
statistically significant association between low levels of
anti-malarial IgG2 antibodies specific to a recombinant
antigen in 131H allele carriers and reduced risk of severe
malaria was also found. Our results also suggest a role for
the 131H/H genotype in protection against clinical
malaria. This may be mediated by enhanced phagocytosis
of P. falciparum-infected erythrocytes by cells expressing
the 131H receptor [53] or by FcγRIIa and FcγRIII-depend-
ent parasite neutralizing activity of monocytes during
antibody-dependent cell-mediated inhibition of parasite
growth [54].
A difference in the degree of association of the FcγRIIa
131R allele with severe malaria observed in the two
regions included in our study may be a reflection of the
nature of immune response against malaria in areas char-
acterized by low and seasonal transmission or endemic
areas with high transmission rates. Although a more
detailed analysis of this is warranted, it may be relevant
that association of high IgG2 levels with protection from
severe P. falciparum malaria observed in the Burkina Faso
study [52] as well as the association of the low IgG2 bind-
ing 131R allele with disease severity in a Sudanese popu-
lation [17] were both carried out from areas characterized
by seasonal P. falciparum malaria transmission. As evident
from the map of P. falciparum incidence in India (Figure
1d) and the distribution of the FcγRIIa AA genotype (Fig-
ure 1c), higher frequency of the protective 131H/H geno-
type was observed in 'high risk' and endemic areas of east
and north-east India. This is suggestive of possible selec-
tion of the protective A allele in populations exposed to P.
falciparum malaria in these regions.
Conclusion
In light of the increasing incidence of P. falciparum malaria
and its concentration in specific regions of India, we initi-
ated a case-control study to understand the role of genetic
variants of specific immune regulatory molecules in
malaria severity/resistance in an endemic and non-
endemic region of the country. Differences in frequencies
of TNF enhancer and FCGR2A SNPs were observed in
populations from the two regions. Association of specific
TNF and FCGR2A SNPs with cytokine levels and disease
severity/resistance was indicated in patients. The TNF
enhancer haplotype carrying the -1031 and -863 SNPs is
the predominant haplotype after the major haplotype in
most Indian populations and correlated with enhanced
TNF levels. In addition, the FcγRIIa 131R low affinity
IgG2-binding allele was associated with susceptibility to
disease with the 131H/H genotype being protective
against P. falciparum malaria. Differences in FcγRIIa allelic
association profiles were observed in regions with differ-
ential P. falciparum prevalence and transmission. The data
underlines the need for addressing the contribution of
human genetic factors in malaria in the context of disease
epidemiology and population genetic substructure within
India.
Abbreviations
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